TREATMENT OF INFLAMMATORY DERMATOSES Adults: Fluticasone propionate cream is a potent topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; these include the following: • Atopic dermatitis • Nummular dermatitis (discoid eczemas) • Prurigo nodularis • Psoriasis (excluding widespread plaque psoriasis) • Lichen simplex chronicus (neurodermatitis) and lichen planus • Seborrhoeic dermatitis • Irritant or allergic contact dermatitis • Discoid lupus erythematosus • An adjunct to systemic steroid therapy in generalised erythroderma • Insect bite reactions • Miliaria (prickly heat) Children : For children and infants aged three months and over who are unresponsive to lower potency corticosteroids, Cutivate cream is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis under the supervision of a specialist. Expert opinion should be sought prior to the use of Cutivate cream in other corticosteroid-responsive dermatoses in children.
TREATMENT OF INFLAMMATORY DERMATOSES Adults: Fluticasone propionate ointment is a potent topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; these include the following: • Atopic dermatitis • Nummular dermatitis (discoid eczemas) • Prurigo nodularis • Psoriasis (excluding widespread plaque psoriasis) • Lichen simplex chronicus (neurodermatitis) and lichen planus • Seborrhoeic dermatitis • Irritant or allergic contact dermatitis • Discoid lupus erythematosus • An adjunct to systemic steroid therapy in generalised erythroderma • Insect bite reactions • Miliaria (prickly heat) Children: For children and infants aged three months and over who are unresponsive to lower potency corticosteroids, Cutivate ointment is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis under the supervision of a specialist. Expert opinion should be sought prior to the use of Cutivate ointment in other corticosteroid-responsive dermatoses in children.
Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...
Galderma announced that the FDA approved Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Trifarotene is the first...
Galderma Laboratories, L.P. has announced on 24 December 2014 the FDA approved Soolantra (ivermectin) Cream, 1% for the once-daily topical...
Dipexium Pharmaceuticals, Inc. announced that the OneStep-1 and OneStep-2 Phase III clinical trials of Locilex (pexiganan cream 0.8%) in patients...
Arcutis Biotherapeutics, Inc. announced that it has commenced pivotal Phase III clinical trials evaluating topical roflumilast cream (ARQ 151) as a potential treatment for atopic dermatitis (AD).
Background: Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis.
Leo Pharma A/S announces that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE)